SCHEDULE: RTW Investments Holds 9.9% Stake in Tenax Therapeutics

RTW Investments, LP and Roderick Wong report beneficial ownership of 2,866,654 shares, representing 9.9% of Tenax Therapeutics, Inc.'s common stock, as of June 30, 2026.

Summary

• RTW Investments, LP and Roderick Wong have filed a Schedule 13G, indicating their beneficial ownership of Tenax Therapeutics, Inc. common stock.
• The filing reports a total of 2,866,654 shares beneficially owned, representing 9.9% of the class of securities.
• This ownership level is subject to a 9.99% beneficial ownership limit due to warrant exercise restrictions.
• The reporting persons are RTW Investments, LP, an investment adviser, and Roderick Wong, M.D., its Managing Partner and Chief Investment Officer.
• The filing date for this amendment is June 30, 2026, with the report date being August 14, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant but controlled stake in Tenax Therapeutics, Inc. by RTW Investments, LP and Roderick Wong. The filing confirms a substantial beneficial ownership without triggering control concerns, suggesting a strategic investment rather than an activist play.

Positives

• RTW Investments, LP and Roderick Wong hold a significant stake (9.9%) in Tenax Therapeutics, Inc., indicating confidence in the company's potential.
• The ownership is structured within regulatory limits (below 9.99% upon warrant exercise), suggesting a strategic, non-controlling investment approach.

Negatives

• The filing does not disclose specific strategic plans or intentions beyond holding the shares, leaving future actions open to interpretation.

Risks

• The ability to exercise all warrants is limited by the 9.99% beneficial ownership threshold, capping the potential stake increase.
• Future stock price performance is subject to the general market risks and specific company-related factors affecting Tenax Therapeutics, Inc.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance from Tenax Therapeutics, Inc. The future outlook for the reporting persons is tied to their investment strategy and the performance of Tenax Therapeutics, Inc.

Management Comments

• The filing should not be construed as an admission that any of the reporting persons are beneficial owners for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. RTW Investments, LP's role as an investment adviser suggests a focus on identifying undervalued or growth-oriented companies like Tenax Therapeutics.

Stakeholder Impact

• Shareholders: The filing indicates a significant investor's continued interest, which could be perceived positively, but the lack of explicit strategy may create uncertainty.
• Management of Tenax Therapeutics: The presence of a substantial shareholder with potential for future influence requires ongoing engagement and performance delivery.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• RTW Investments, LP and Roderick Wong will continue to monitor their investment in Tenax Therapeutics, Inc.
• Future actions may depend on the company's performance and strategic developments.

Key Dates

Keywords

Tenax Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Warrants